We offer several clinical trials for multiple types of cancer and participate in as many as 50 to 100 clinical trials with partnering cancer centers. These clinical trials give our patients access to emerging treatment options right here in Spokane, eliminating the need to travel outside of the Inland Northwest for the latest in cancer treatment. The clinical trials also provide important information to help conquer cancer.
Before beginning treatment, you may want to consider participating in a clinical trial. Talk with your medical oncologist, surgical oncologist or radiation oncologist to determine if this is a good option for you.
What is a clinical trial?
Clinical trials are research studies that help determine the effectiveness of a new drug or treatment. Each clinical trial is designed to answer specific scientific questions and to help find potentially better ways to prevent, diagnose or treat cancer.
Why are clinical trials important?
Clinical trials are a vital part of the process in finding new cancer treatments and ultimately a cure for cancer. Without these research studies, many of the advances we see today in cancer detection, treatment and prevention would never have happened.
For More Information
If you are interested in a clinical trial and would like more information to discuss with our Cancer Care Northwest physician, please email the Cancer Care Northwest Research Department at email@example.com for more information. Be sure to include:
Using the dropdown menu below, you can search and request more information for open trials.
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE).View Details
A Multicenter, Open-Label, Randomized, Controlled Phase 4 Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination with Fulvestrant Compared to Chemotherapy in Women with HR Positive, HER2 Negative Advanced Breast Cancer with Visceral Metastases.View Details
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation.View Details
A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) to evaluate the safety and efficacy of pembrolizumab and lenvatinib as 1L intervention in a PD-L1 selected population of participants with recurrent or metastatic head and neck squamous cell carcinoma.View Details
A Phase 3, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515).View Details
A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975).View Details
A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC).View Details
A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC).View Details
A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer.View Details
A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011).View Details
A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant.View Details
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Superoxide Dismutase Mimetic GC4419 to Reduce Severe Oral Mucositis (SOM) Associated with Chemoradiotherapy for Locally Advanced, Non-Metastatic Head and Neck CancerView Details